[go: up one dir, main page]

ZA200603681B - Interleukin-10 antibodies - Google Patents

Interleukin-10 antibodies

Info

Publication number
ZA200603681B
ZA200603681B ZA200603681A ZA200603681A ZA200603681B ZA 200603681 B ZA200603681 B ZA 200603681B ZA 200603681 A ZA200603681 A ZA 200603681A ZA 200603681 A ZA200603681 A ZA 200603681A ZA 200603681 B ZA200603681 B ZA 200603681B
Authority
ZA
South Africa
Prior art keywords
interleukin
antibodies
Prior art date
Application number
ZA200603681A
Other languages
English (en)
Inventor
Leonard G Presta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200603681B publication Critical patent/ZA200603681B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
ZA200603681A 2003-11-10 2006-05-09 Interleukin-10 antibodies ZA200603681B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51899903P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
ZA200603681B true ZA200603681B (en) 2010-01-27

Family

ID=34590335

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603681A ZA200603681B (en) 2003-11-10 2006-05-09 Interleukin-10 antibodies

Country Status (25)

Country Link
US (5) US20050101770A1 (xx)
EP (4) EP1694705B1 (xx)
JP (4) JP4762148B2 (xx)
KR (3) KR20120023858A (xx)
CN (2) CN100595212C (xx)
AR (3) AR046833A1 (xx)
AT (1) ATE440867T1 (xx)
AU (2) AU2004290044B2 (xx)
CA (2) CA2545255C (xx)
CY (1) CY1110557T1 (xx)
DE (1) DE602004022855D1 (xx)
DK (1) DK1694705T3 (xx)
ES (1) ES2329907T3 (xx)
HR (1) HRP20090517T1 (xx)
IL (3) IL175523A (xx)
NO (1) NO20062672L (xx)
NZ (1) NZ546632A (xx)
PE (3) PE20050925A1 (xx)
PL (1) PL1694705T3 (xx)
PT (1) PT1694705E (xx)
RS (1) RS51180B (xx)
SG (1) SG155205A1 (xx)
SI (1) SI1694705T1 (xx)
WO (2) WO2005047324A2 (xx)
ZA (1) ZA200603681B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500247A (ja) * 2000-12-07 2005-01-06 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム ヒトｍｄａ−７に関わる処置方法
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2003075952A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
EP1718229B1 (de) * 2004-02-23 2008-04-02 Synthes GmbH Knochenschraube
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
KR101379364B1 (ko) * 2005-02-08 2014-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 ｍｄａ-7을 포함하는 조성물
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
SI2066695T1 (sl) * 2006-09-05 2013-05-31 Eli Lilly And Company Protitelo proti miostatinu
EP2628752A1 (en) 2006-12-14 2013-08-21 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
CA2674831A1 (en) 2006-12-22 2008-11-13 Schering Corporation 5,6-ring annulated indole derivatives and methods of use thereof
US8212008B2 (en) * 2006-12-22 2012-07-03 Schering Corporation Antibodies to CD200R
JP5079818B2 (ja) 2006-12-22 2012-11-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
JP5211068B2 (ja) * 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
TR201821029T4 (tr) 2007-02-23 2019-01-21 Merck Sharp & Dohme Geliştirilmiş antı-IL-23p19 antikorları.
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
AR068108A1 (es) * 2007-08-29 2009-11-04 Schering Corp Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
PE20090995A1 (es) * 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
AR068106A1 (es) 2007-08-29 2009-11-04 Schering Corp Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
AP2011005859A0 (en) * 2009-02-23 2011-10-31 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to CD19 and their uses.
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
CA2782007C (en) * 2009-11-30 2018-07-24 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
MX2012010392A (es) 2010-03-09 2012-10-03 Merck Sharp & Dohme Compuesto de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EP4269563A3 (en) 2010-06-19 2024-01-10 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
KR20130119948A (ko) 2010-11-23 2013-11-01 글락소 그룹 리미티드 온코스타틴 ｍ (ｏｓｍ)에 대한 항원 결합 단백질
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
CA2903576C (en) 2013-03-15 2021-06-08 Nai-Kong V. Cheung High affinity anti-gd2 antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN105277638A (zh) * 2014-07-22 2016-01-27 沈鹤霄 一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2017145559A (ru) * 2015-05-29 2019-07-03 Мерк Шарп И Доум Корп. Комбинация антитела к il-10 и олигонуклеотида типа cpg-c для лечения рака
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
BR112018010084A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1 e/ou lag3
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
US20190010224A1 (en) * 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
CA3118144A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US20240092886A1 (en) * 2019-10-09 2024-03-21 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds
AU2021383537A1 (en) 2020-11-18 2023-06-29 Astrazeneca Ab Steroid sparing
CN118043349B (zh) * 2021-06-11 2024-11-15 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2024091417A1 (en) * 2022-10-24 2024-05-02 Merck Sharp & Dohme Llc Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0600970B1 (en) * 1991-08-06 1999-12-08 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP0671933B1 (en) * 1992-08-20 1998-02-04 Schering Corporation Novel uses of il-10
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
US7034121B2 (en) * 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2463927A1 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

Also Published As

Publication number Publication date
ES2329907T3 (es) 2009-12-02
PL1694705T3 (pl) 2010-02-26
RS51180B (sr) 2010-10-31
NZ546632A (en) 2009-07-31
SI1694705T1 (sl) 2010-01-29
KR20060120093A (ko) 2006-11-24
PT1694705E (pt) 2009-11-30
SG155205A1 (en) 2009-09-30
EP1694705B1 (en) 2009-08-26
EP2292661A3 (en) 2011-06-22
AU2011200606B2 (en) 2012-05-10
NO20062672L (no) 2006-06-09
PE20050925A1 (es) 2005-11-29
PE20090047A1 (es) 2009-01-26
IL202681A0 (en) 2010-06-30
CN102010471A (zh) 2011-04-13
JP2011087590A (ja) 2011-05-06
WO2005047326A2 (en) 2005-05-26
KR20120025618A (ko) 2012-03-15
CA2812856A1 (en) 2005-05-26
IL202682A0 (en) 2010-06-30
AU2004290044A1 (en) 2005-05-26
CA2545255C (en) 2013-06-25
IL175523A (en) 2011-01-31
AR074780A2 (es) 2011-02-09
WO2005047324A2 (en) 2005-05-26
AR046833A1 (es) 2005-12-28
EP2292661A2 (en) 2011-03-09
HRP20090517T1 (hr) 2009-10-31
KR101175055B1 (ko) 2012-08-22
DE602004022855D1 (de) 2009-10-08
US20050101770A1 (en) 2005-05-12
AR074779A2 (es) 2011-02-09
HK1087722A1 (en) 2006-10-20
US8226947B2 (en) 2012-07-24
PE20090046A1 (es) 2009-01-26
CY1110557T1 (el) 2015-04-29
IL202681A (en) 2011-10-31
AU2011200606A1 (en) 2011-03-03
IL175523A0 (en) 2006-09-05
AU2004290044B2 (en) 2010-11-18
EP1694705A2 (en) 2006-08-30
US20100203049A1 (en) 2010-08-12
ATE440867T1 (de) 2009-09-15
US20140112919A1 (en) 2014-04-24
US20120282253A1 (en) 2012-11-08
CA2545255A1 (en) 2006-05-05
EP2128175A1 (en) 2009-12-02
US7662379B2 (en) 2010-02-16
DK1694705T3 (da) 2009-12-07
JP2008500020A (ja) 2008-01-10
JP2014014361A (ja) 2014-01-30
JP2011062211A (ja) 2011-03-31
WO2005047326A3 (en) 2005-12-22
CN100595212C (zh) 2010-03-24
EP2123678A1 (en) 2009-11-25
US8624013B2 (en) 2014-01-07
JP4762148B2 (ja) 2011-08-31
KR20120023858A (ko) 2012-03-13
US20070178097A1 (en) 2007-08-02
CN1906213A (zh) 2007-01-31

Similar Documents

Publication Publication Date Title
IL202681A0 (en) Interleukin-10 antibodies
EP1616881A4 (en) ANTI-MPL ANTIBODIES
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
GB0426043D0 (en) Antibodies
PL375405A1 (en) Antibodies
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
PT1599504E (pt) Anticorpo modificado
IL173557A0 (en) Variable antibodies
GB0306618D0 (en) Antibody
IL172511A0 (en) Specific human antibodies
GB0226878D0 (en) Antibodies
GB0302699D0 (en) Immunoglobulin
GB0311108D0 (en) Proteins
GB0329711D0 (en) Antibodies
GB0317974D0 (en) Novel antibodies
GB0218235D0 (en) Antibodies
GB0218234D0 (en) Antibodies
GB0218232D0 (en) Antibodies
GB0218230D0 (en) Antibodies
GB0218229D0 (en) Antibodies
GB0210508D0 (en) Antibodies
GB0203018D0 (en) Antibodies
GB0217742D0 (en) Novel antibodies
GB0319118D0 (en) Variable antibodies
GB0319345D0 (en) Variable antibodies